Euglycaemic ketoacidosis in a postoperative Whipple patient using canaglifozin
Authors:
- 27 September 2016
- journal article
- Published by BMJ in BMJ Case Reports
- Vol. 2016
Abstract
SGLT2 inhibitors are a new class of oral antihyperglycaemic agents that have garnered much attention for their attractive efficacy profile in glycaemic control along with the added benefit of weight loss. There has been increasing concern for the risk of euglycaemic (serum glucose 4–8 mmol/L) ketoacidosis with these agents. In the setting of a postoperative patient, the use of these drugs may exacerbate the normal physiological stresses of the body and increase the risk of developing euglycaemic ketoacidosis (euKDA). This case highlights a postoperative patient who was using an SGLT2 inhibitor and developed severe euKDA after a pancreaticoduodenectomy. The goal of this case report was to bring awareness to the possibility of this rare adverse event. In doing so, it may aid in preoperative planning of the diabetic patient and trigger appropriate management for those who develop euKDA.Keywords
This publication has 7 references indexed in Scilit:
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 InhibitorsDiabetes Care, 2015
- Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical ProgramDiabetes Care, 2015
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 InhibitionDiabetes Care, 2015
- Euglycemic diabetic ketoacidosis, a misleading presentation of diabetic ketoacidosisNorth American Journal of Medical Sciences, 2015
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes MellitusDrugs, 2014
- Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical PharmacologyDiabetes Therapy, 2014
- Hyperglycemic Crises in Adult Patients With DiabetesDiabetes Care, 2009